A total of 6 cycles of CHOP-like chemotherapy plus rituximab (R-CHOP) are the standard of care for younger patients with diffuse large B-cell lymphoma (DLBCL). The MInT trial (NCT00400907) established a DLBCL subgroup with favourable prognosis as defined as aaIPI=0 and no bulky disease; giving rise to the question of whether 4 cycles of CHOP plus 6 applications of rituximab were non-inferior to the standard treatment in this population. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Viola Poeschel, MD, of Saarland University Medical School, Homburg, Germany, presents the results of the Phase III study (FLYER; NCT00278421) which investigated this. This revealed that 4x R-CHOP + 2xR was non-inferior to the standard 6x R-CHOP, meaning that chemotherapy can be spared in this population without comprimising on the outlook of these patients. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
